| Literature DB >> 31013607 |
Md Mamunul Haque1, Dhiraj P Murale2, Yun Kyung Kim3,4, Jun-Seok Lee5,6.
Abstract
Tauopathy is a collective term for neurodegenerative diseases associated with pathological modifications of tau protein. Tau modifications are mediated by many factors. Recently, reactive oxygen species (ROS) have attracted attention due to their upstream and downstream effects on tauopathy. In physiological conditions, healthy cells generate a moderate level of ROS for self-defense against foreign invaders. Imbalances between ROS and the anti-oxidation pathway cause an accumulation of excessive ROS. There is clear evidence that ROS directly promotes tau modifications in tauopathy. ROS is also highly upregulated in the patients' brain of tauopathies, and anti-oxidants are currently prescribed as potential therapeutic agents for tauopathy. Thus, there is a clear connection between oxidative stress (OS) and tauopathies that needs to be studied in more detail. In this review, we will describe the chemical nature of ROS and their roles in tauopathy.Entities:
Keywords: oxidative stress; reactive oxygen species; tauopathy
Mesh:
Substances:
Year: 2019 PMID: 31013607 PMCID: PMC6514575 DOI: 10.3390/ijms20081959
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Oxidative stress-mediated tauopathy.
Figure 2Electronic configuration of reactive oxygen species (ROS).
Figure 3Standard reduction potentials of ROS formation via energy or electron transfer reactions of molecular oxygen.
Figure 4Physiological condition versus tauopathy condition by oxidative stress generation.
Potential oxidative markers in tauopathies (up-regulation is labeled as up-arrow, and down-regulation is labeled as down-arrow).
| OS Markers | AD | PSP | PiD | CBD | FTD | FTDP-17 | FTLD | PD |
|---|---|---|---|---|---|---|---|---|
|
| ↓ [ | ↑ [ | ↑ [ | ↑ [ | ||||
|
| ↓ [ | ↑ [ | ↓ [ | ↑ [ | ↑ [ | |||
|
| ↓ [ | ↑ [ | ↑ [ | |||||
|
| ↓ [ | ↑ [ | ↓ [ | ↓ [ | ||||
|
| ↓ [ | ↓ [ | ||||||
|
| ↓ [ | ↓ [ | ||||||
|
| ↓ [ | ↑ [ | ↑ [ | ↑ [ | ||||
|
| ↑ [ | ↑ [ | ↑ [ | ↑ [ | ||||
|
| ↑ [ | ↑ [ | ↑ [ | ↑ [ | ||||
|
| ↑ [ | ↑ [ | ↑ [ | ↑ [ | ↑ [ | |||
|
| ↓ [ | |||||||
|
| ↓ [ | ↓ [ | ||||||
|
| ↓ [ | ↓ [ | ||||||
|
| ↑ [ | ↑ [ | ↑ [ | ↑ [ | ↑ [ | ↑ [ | ||
|
| ↑ [ | ↑ [ | ↑ [ | |||||
|
| ↑ [ | ↑ [ | ||||||
|
| ↑ [ | ↑ [ | ||||||
|
| ↑ [ | ↑ [ | ||||||
|
| ↑ [ | |||||||
|
| ↑ [ | |||||||
|
| ↑ [ | |||||||
|
| ↓ [ | |||||||
|
| ↓ [ |
ROS and their mode of detection using fluorescent probes.
| ROS | Fluorescent Probe | Reaction | Examples |
|---|---|---|---|
|
| H2O2-induced oxidation of arylboronate ester to phenols. |
| |
|
| Nucleophilic substitution reaction of superoxide with the probes where the leaving group is phosphinate group [ |
| |
|
| Hydroxyl radical-mediated oxidation of leuco forms of fluorescent dyes and nitroxide moiety. |
| |
|
| The fluorescent probes for singlet oxygen have been developed based on the [2 + 4] cycloaddition where singlet oxygen acts as a strong dienophile [ |
| |
|
| Peroxynitrite-mediated oxidation of chalcogenides (S, Se, and Te), boronic acids or boronates, hydrazides, cleavage of C–C double bonds and oxidative |
| |
|
| NO-mediated reaction of O-diaminophenyl group with NO to generate the triazole. |
| |
|
| Hypochlorite mediated spiro-ring opening of the xanthene probes and oxidation of catechol to benzoquinone [ |
|
Therapeutic approaches of tauopathies related to ROS.
| Therapeutic Approaches | Chemical Agents | Treating Route and Doses | Experimental Model | Reference |
|---|---|---|---|---|
|
| Curcumin | 10 μg/mL for 1 h | Aβ treated PC12 cell | [ |
| Methylene blue | 4 mg/kg in diet | TauP301S mouse | [ | |
| CoQ10 | 0.5% in diet | TauP301S mouse | [ | |
| Paraquant | 30 mM in diet for 48 h | TauR406W drosophila | [ | |
| Sulforaphane | 5 mg/kg twice a week by intraperitoneally | C57Bl/66-OHDA mouse | [ | |
| BR 297 | 500 nM for 24 h | APP treated SH-SY5Y cell | [ | |
| S14 | 5 mg/Kg/daily for 4 weeks by intraperitoneally | Tg2576APP/PS1 AD mouse | [ | |
| Resveratrol | 500–1000 mg/daily for 26 months by orally | AD patients | [ | |
|
| EUK-207 | 3.41 mM/day for 28 days by micro-osmotic pump | C57BL/6/129S-3xTg-AD mouse | [ |
|
| Ascorbic acid | 250–500 μM for 24 h | Neurons form Tau151–391 rat | [ |
| α-tocopherol | 0.5–1.5 mM in diet for 10 days | tauR406W drosophila | [ | |
| 49 IU/Kg in diet | B6D2/F1-tau44 mouse | [ | ||
| 2000 IU/day for 6 months | AD patient | [ | ||
| Tocotrienol | 5 mg/Kg/day for 15 months by orally | APPswe/PS1dE9 mouse | [ | |
|
| Clioquinol | 30 mg/kg/day for 5 weeks by orally | TgCRND8-AD mouse | [ |
| PBT2 | 250 mg/day for 12 weeks by orally | AD patient | [ | |
| CuIIGTSM | 10 mg/kg/daily by orally | APP/PS1 AD mouse | [ | |
| Desferrioxamine | 125 mg twice daily/5 days per week for 24 months by intramuscularly | AD patient | [ |